Innate Pharma (IPHA) Short Interest Ratio & Short Volume

Short interest is the volume of Innate Pharma shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 386,100 shares of IPHA short. 0.68% of Innate Pharma's shares are currently sold short. Learn More on Innate Pharma's current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IPHA shares currently have a short interest ratio of 2.0. Learn More on Innate Pharma's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.68% of Innate Pharma's floating shares are currently sold short.

Innate Pharma saw a decline in short interest during the month of April. As of April 15th, there was short interest totaling 386,100 shares, a decline of 5.2% from the previous total of 407,300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.68% of Innate Pharma's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Innate Pharma: Xeris Biopharma Holdings, Inc. (13.39%), Dianthus Therapeutics, Inc. (26.50%), AnaptysBio, Inc. (53.39%), KalVista Pharmaceuticals, Inc. (14.04%), Arbutus Biopharma Co. (6.07%), Trevi Therapeutics, Inc. (10.17%), ChromaDex Co. (4.29%), Pharming Group (0.00%), Organogenesis Holdings Inc. (15.86%), CorMedix Inc. (14.36%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($21.71 billion), iShares 20+ Year Treasury Bond ETF ($9.48 billion), Strategy Incorporated ($8.92 billion), Charter Communications, Inc. ($3.86 billion), Apollo Global Management, Inc. ($3.86 billion), Capital One Financial Co. ($3.72 billion), Super Micro Computer, Inc. ($3.47 billion), AppLovin Co. ($2.64 billion), VanEck Semiconductor ETF ($2.46 billion), and The Kroger Co. ($2.33 billion). View all of the most shorted stocks.

Short selling IPHA is an investing strategy that aims to generate trading profit from Innate Pharma as its price is falling. IPHA shares are trading up $0.03 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Innate Pharma occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IPHA, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IPHA, twice per month. The most recent reporting period available is April, 15 2025.